期刊文献+

磁共振多参数成像及动态增强扫描诊断前列腺癌的价值

下载PDF
导出
摘要 目的:分析前列腺癌诊断中磁共振多参数成像及动态增强扫描的价值。方法:回顾性选取2020年2月—2023年2月济南市章丘区人民医院收治的前列腺病变患者50例,依据疾病类型分为前列腺癌组(20例)、良性前列腺增生组(30例)。以手术病理或穿刺活检结果为金标准,统计分析磁共振双参数成像(MRI+DWI)与多参数成像(MRI+DWI+DCE)的诊断效能,比较两组病灶磁共振动态增强参数、曲线。结果:50例患者中,手术病理或穿刺活检恶性20例,感兴趣区(ROI)34个,其中低分化癌灶18个,中分化癌灶13个,高分化癌灶3个;良性30例,ROI 96个,其中以腺体增生为主的结节灶47个,以基质增生为主的结节灶49个。MRI+DWI+DCE检查前列腺病变的灵敏度、特异度、准确率、阳性预测值、阴性预测值均高于MRI+DWI,差异有统计学意义(P<0.05)。前列腺癌组患者的病灶磁共振增强参数中达峰时间(Tmax)短于良性前列腺增生组,最快强化率(Ramx)、流出分数(Washout)均高于良性前列腺增生组,差异有统计学意义(P<0.05),但两组患者的最大强化程度(SImax)对比,差异无统计学意义(P>0.05)。前列腺癌组患者的病灶磁共振增强曲线呈速升缓降型、速升平台型比例均高于良性前列腺增生组,呈缓升平台型、持续缓升型比例均低于良性前列腺增生组,差异有统计学意义(P<0.05)。结论:前列腺癌诊断中磁共振多参数成像及动态增强扫描的价值较高,其可获取SI-T曲线及半定量参数,提供血液灌注信息,从而对前列腺良恶性疾病的组织特征进行进一步了解。
作者 王金华
出处 《影像研究与医学应用》 2024年第12期89-91,共3页 Journal of Imaging Research and Medical Applications
  • 相关文献

参考文献13

二级参考文献92

  • 1[1]Greenlee RT, Murray T,Thun M e al. Cancer statistics[J].CA Cancer J Clin, 2001, 51: 15-36.
  • 2[2]La Rosa F, Stracci F, Petrinelli AM,et al. Incidence, mortality and long-term survival from prostate cancer in Umbria, Italy, 1978-1994[J].Eur Urol,2000, 38(4):388-392.
  • 3[3]Majeed A, Babb P, Jones J,et al. Trends in prostate cancer incidence,mortality and survival in England and Wales 1971-1998[J].BJU Int,2000, 85(9):1058-1062.
  • 4[4]Brewster DH, Fraser LA, Harris V,et al. Rising incidence of prostate cancer in Scotland: increased risk or increased detection?[J].BJU Int,2000, 85(4):463-472.
  • 5[5]Levi F, La Vecchia C, Randimbison L,et al. Incidence,mortality and survival from prostate cancer in Vaud and Neuchatel, Switzerland, 1974-1994[J].Ann Oncol, 1998, 9(1):31-35.
  • 6[6]Grosclaude P, Menegoz F, Schaffer P,et al. Prostate cancer screening (Ⅱ):is prostate cancer a public health problem?Update of incidence and mortality figures in France from 1982 to 1990[J].Prog Urol, 1997, 7(4):647-654.
  • 7[7]Cook LS, Goldoft M, Schwartz SM,et al. Incidence of adenocarcinoma of prostate in Asian immigrants to the United States and their descendants [J].J Urol, 1999, 161:152-155.
  • 8[8]Allen NE,Forest MS,Key TJ.The association between polymorphism in the CYP17 gene and SRD5A2 gene and serum androgen concentration in men[J].Cancer Epidemiol Biomark Prev,2001, 10: 185 - 189.
  • 9[9]Haiman CA, Stampfer MJ, Giovannucci E,et al. The relationship between a polymorphism in CYP17 gene with plasma hormone level and prostate cancer[J].Cancer Epidemiol Biomark Prev. 2001, 10:743-748.
  • 10[10]Stanford JL, Noonan EA,Iwasaki L,et al. A polymorphism in the CYP17 gene and risk of prostate cancer[J].Cancer Epidemiol Biomarkers Prev, 2002, 11(3):243-247.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部